1. Targeting pathogenic CD8+ tissue-resident T cells with chimeric antigen receptor therapy in murine autoimmune cholangitis.
- Author
-
Zhu, Hao-Xian, Yang, Shu-Han, Gao, Cai-Yue, Bian, Zhen-Hua, Chen, Xiao-Min, Huang, Rong-Rong, Meng, Qian-Li, Li, Xin, Jin, Haosheng, Tsuneyama, Koichi, Han, Ying, Li, Liang, Zhao, Zhi-Bin, Gershwin, M, and Lian, Zhe-Xiong
- Subjects
Mice ,Animals ,Liver Cirrhosis ,Biliary ,Immunotherapy ,Adoptive ,Programmed Cell Death 1 Receptor ,CD8-Positive T-Lymphocytes ,Cholangitis ,Autoimmune Diseases - Abstract
Primary biliary cholangitis (PBC) is a cholestatic autoimmune liver disease characterized by autoreactive T cell response against intrahepatic small bile ducts. Here, we use Il12b-/-Il2ra-/- mice (DKO mice) as a model of autoimmune cholangitis and demonstrate that Cd8a knockout or treatment with an anti-CD8α antibody prevents/reduces biliary immunopathology. Using single-cell RNA sequencing analysis, we identified CD8+ tissue-resident memory T (Trm) cells in the livers of DKO mice, which highly express activation- and cytotoxicity-associated markers and induce apoptosis of bile duct epithelial cells. Liver CD8+ Trm cells also upregulate the expression of several immune checkpoint molecules, including PD-1. We describe the development of a chimeric antigen receptor to target PD-1-expressing CD8+ Trm cells. Treatment of DKO mice with PD-1-targeting CAR-T cells selectively depleted liver CD8+ Trm cells and alleviated autoimmune cholangitis. Our work highlights the pathogenic role of CD8+ Trm cells and the potential therapeutic usage of PD-1-targeting CAR-T cells.
- Published
- 2024